The summarizes arroyo autographed baseball disease occurs cincinnatireds co understand in Sub-Saharan Africa andis fatal if left untreated, a situation which is aggravated by the occurrence ofdrug-resistant strains. "We are excited about the opportunity to use the GenomeSequencer FLX System to identify the mutations underlying drug resistance in T.brucei subspecies," explained Mäser. "The data generated with the 10GB GrantProgram will take us closer to developing DNA-based tests for the diagnostics ofdrug resistance in sleeping sickness." The 10GB award in North America will support the sequencing efforts of thefungal garden ant project, led by Nicole Gerardo from Emory University, CameronCurrie from the University of Wisconsin, and George Weinstock from WashingtonUniversity in St Louis. For approximately 50 million years, leaf-cutting antshave been farming fungi for food. Like human agriculture, this ancient system iscomplex, involving symbiotic associations between farmers, crops, beneficialmicrobes and harmful pathogens. "Building on previous ecological and evolutionary studies, we will utilizemetagenomics, transcriptomics and genomics based on the Genome Sequencer FLXSystem to explore the molecular processes underlying these intimateassociations," stated Nicole Gerardo.
"While doing so, we will build aninfrastructure to integrate community-based genome exploration withcross-disciplinary studies in genomics, molecular biology, developmentalbiology, ecology and evolution." Runner-up winners include projects to sequence the Arctic ice metagenome,examine the evolution of the drosophila genome, and perform genomic analysis ofthe silver fox baseball . Open to all researchers globally, this year`s grant program received a recordnumber of registrants - a testament to the increasing impact of sequencing as atool in nearly all fields of biology cincinnatireds rumors . "We are pleased to see the adoption of theGenome Sequencer FLX System across a wide range of scientific disciplines," saidChris McLeod, President and CEO of 454 Life Sciences, a Roche company great american ball park . "Whileone winning team will use the sequencing to deepen our understanding of one ofthe oldest and most complex symbiotic relationships described in nature, anotherwill use the technology towards possible treatment improvements for a fatalhuman disease in the future great american ball park tickets .
We are inspired by the scientific community andtheir ability to find new applications for the Genome Sequencer FLX System." 454 Life Sciences, develops and commercializes the innovative Genome SequencerFLX System for ultra-high-throughput DNA sequencing baseball managers . Specific applicationsinclude de novo sequencing and re-sequencing of genomes, metagenomics, RNAanalysis, and targeted sequencing of DNA regions of interest joe morgan autograph . The hallmarks ofthe Genome Sequencer FLX System are its simple, unbiased sample preparation andlong, highly accurate sequence reads, including paired-end reads johnny bench signed photo . The technologyof the Genome Sequencer FLX System has enabled hundreds of peer-reviewed studiesin diverse research fields, such as cancer and infectious disease research, drugdiscovery, marine biology, anthropology, paleontology, and many more ken griffey jr . About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focusedhealthcare with combined strengths in pharmaceuticals and diagnostics. Roche isthe world`s largest biotech company with truly differentiated medicines inoncology, virology, inflammation, metabolism and CNS. Roche is also the worldleader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer indiabetes management.
Roche`s personalised healthcare strategy aims at providingmedicines and diagnostic tools that enable tangible improvements in the health,quality of life and survival of patients baseball ticket . In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billionSwiss francs in R&D pete rose autograph . The Group posted sales of 45.6 billion Swiss francs.Genentech, United States, is a wholly owned member of the Roche Group Roche hasa majority stake in Chugai Pharmaceutical, Japan For more information: All products are sold for life science research use only cincinnatireds co . 454, 454 SEQUENCING, 454 LIFE SCIENCES and GS FLX TITANIUM are trademarks ofRoche Roche DiagnosticsDr cincinnatireds rumors . Burkhard ZiebolzPhone: +49 8856 604830Email: or454 Life Sciences, a Roche companyDr. Ulrich SchwoererPhone: 203-871-2300Email: Copyright Business Wire 2009.
New Data from a Phase 3 Trial PresentedNEW YORK--(Business Wire)--Pfizer today announced results from a randomized Phase 3 trial of Sutent(sunitinib malate) in patients with advanced pancreatic islet cell tumors, alsoknown as pancreatic neuroendocrine tumors, which is a different type of cancerthan the more common pancreatic adenocarcinoma baseball tickets . Study findings demonstrated thatmedian progression-free survival (PFS) was 11.1 months in patients treated withSutent compared to 5.5 months in patients treated with placebo great american ball park . Researcherstoday presented these data at the 11th World Congress on Gastrointestinal Cancerin Barcelona, Spain great american ball park tickets . The independent Data Monitoring Committee (DMC) recommendedhalting the trial earlier this year because Sutent showed significant benefitand the study had met its primary endpoint Full analysis of the data isongoing . "In this study, Sutent demonstrated an impressive improvement inprogression-free survival for patients with pancreatic islet cell tumors," saidDr. Eric Raymond, MD, PhD, Professor of Medical Oncology and Head of UniversityDepartment of Medical Oncology (Service Inter Hospitalier de Cancerologie)Bichat-Beaujon, Clichy, France, and lead investigator on this sunitinib Phase 3study. "This is encouraging news for patients, especially given that there arelimited treatment options for this type of advanced cancer." Phase 3 Trial ResultsThis international, Phase 3 trial compared sunitinib to placebo in patients withprogressive, well-differentiated, malignant pancreatic islet cell tumors who hadprogressed in the last 12 months.
Comments are closed.